Narcolepsy

Sleepiness: Causes, Consequences and Treatment

Volumn , Issue , 2011, Pages 111-125

  Van Der Heide, Astrid ^a   Lammers, Gert Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876474001     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511762697.013     Document Type: Chapter

References (62)

1. American Academy of Sleep Medicine. International Classification of Sleep Disorders, Diagnostic and Coding Manual. (2nd Ed.)Westchester, IL: American Academy of Sleep Medicine, 2005.
2. Silber MH, Krahn L E, Olson E J, et al.The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep, 2002; 25:197–202.
3. Longstreth WT, Jr., Koepsell T D, Ton T G, et al.The epidemiology of narcolepsy. Sleep, 2007; 30:13–26.
4. Overeem S, Mignot E, van Dijk J G, et al.Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol, 2001; 18:78–105.
5. Dauvilliers Y, Montplaisir J, Molinari N, et al.Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology, 2001; 57:2029–33.
6. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet, 2007; 369:499–511.
7. Guilleminault C. Cataplexy. In: Guilleminault C, Dement WC and Passouant P., Eds. Narcolepsy. New York, NY: Spectrum, 1976: 125–44.
8. Fortuyn H A, Lappenschaar G A, Nienhuis F J, et al.Psychotic symptoms in narcolepsy: phenomenology and a comparison with schizophrenia. Gen Hosp Psychiatry, 2009; 31:146–54.
9. Ohayon MM, Priest R G, Zulley J, et al.Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology, 2002; 58:1826–33.
10. Ohayon MM. From wakefulness to excessive sleepiness: what we know and still need to know. Sleep Med Rev, 2008; 12:129–41.
11. Broughton R, Dunham W, Newman J, et al.Ambulatory 24 hour sleep–wake monitoring in narcolepsy–cataplexy compared to matched controls. Electroencephalogr Clin Neurophysiol, 1988; 70:473–81.
12. Kok SW, Overeem S, Visscher T L, et al.Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res, 2003; 11:1147–54.
13. Sansa G, Iranzo A, Santamaria J. Obstructive sleep apnea in narcolepsy. Sleep Med, 2010; 11:93–95.
14. Dauvilliers Y, Pennestri M H, Petit D, et al.Periodic leg movements during sleep and wakefulness in narcolepsy. J Sleep Res, 2007; 16:333–39.
15. Nightingale S, Orgill J C, Ebrahim I O, et al.The association between narcolepsy and REM behavior disorder (RBD). Sleep Med, 2005; 6:253–58.
16. Broughton R, Ghanem Q, Hishikawa Y, et al.Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls. Can J Neurol Sci, 1981; 8:299–304.
17. Mignot E, Lammers G J, Ripley B, et al.The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol, 2002; 59:1553–62.
18. Arand D, Bonnet M, Hurwitz T, et al.The clinical use of the MSLT and MWT. Sleep, 2005; 28:123–44.
19. Marti I, Valko P O, Khatami R, et al.Multiple sleep latency measures in narcolepsy and behaviourally induced insufficient sleep syndrome. Sleep Med, 2009; 10:1146–50.
20. Sakurai T, Amemiya A, Ishii M, et al.Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell, 1998; 92:573–85.
21. de Lecea L, Kilduff T S, Peyron C, et al.The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A, 1998; 95:322–27.
22. Lin L, Faraco J, Li R, et al.The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell, 1999; 98:365–76.
23. Chemelli RM, Willie J T, Sinton CM, et al.Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell, 1999; 98:437–51.
24. Nishino S, Ripley B, Overeem S, et al.Hypocretin (orexin) deficiency in human narcolepsy. Lancet, 2000; 355:39–40.
25. Thannickal T C, Siegel JM, Nienhuis R, et al.Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol, 2003; 13:340–51.
26. Thannickal T C, Moore R Y, Nienhuis R, et al.Reduced number of hypocretin neurons in human narcolepsy. Neuron, 2000; 27:469–74.
27. Thannickal T C, Nienhuis R, Siegel JM. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep, 2009; 32:993–98.
28. Saper C B, Chou T C, Scammell T E. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci, 2001; 24:726–31.
29. Saper C B, Scammell T E, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature, 2005; 437:1257–63.
30. Broughton R, Valley V, Aguirre M, et al.Excessive daytime sleepiness and the pathophysiology of narcolepsy–cataplexy: a laboratory perspective. Sleep, 1986; 9:205–15.
31. Peyron C, Faraco J, Rogers W, et al.A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med, 2000; 6:991–97.
32. Mignot E. Genetic and familial aspects of narcolepsy. Neurology, 1998; 50:S16–22.
33. Lin L, Hungs M, Mignot E. Narcolepsy and the HLA region. J Neuroimmunol, 2001; 117:9–20.
34. Overeem S, Black J L, III, Lammers G J. Narcolepsy: immunological aspects. Sleep Med Rev, 2008; 12:95–107.
35. Tanaka S, Honda Y, Inoue Y, et al.Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. Sleep, 2006; 29:633–38.
36. Black J L, III, Silber MH, Krahn L E, et al.Studies of humoral immunity to preprohypocretin in human leukocyte antigen DQB1∗0602-positive narcoleptic subjects with cataplexy. Biol Psychiatry, 2005; 58:504–09.
37. Black J L, III, Silber MH, Krahn L E, et al.Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. Sleep, 2005; 28:427–31.
38. Cvetkovic V, Bayer L, Dorsaz S, et al.Tribbles homolog 2 as an autoantigen in human narcolepsy. J Clin Invest, 2010; 120:713–19.
39. Hallmayer J, Faraco J, Lin L, et al.Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet, 2009; 41:708–11.
40. Mullington J, Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy–cataplexy. Sleep, 1993; 16:444–56.
41. Bruck D, Armstrong S, Coleman G. Sleepiness after glucose in narcolepsy. J Sleep Res, 1994; 3:171–79.
42. Fronczek R, Middelkoop H A, van Dijk J G, et al.Focusing on vigilance instead of sleepiness in the assessment of narcolepsy: high sensitivity of the Sustained Attention to Response Task (SART). Sleep, 2006; 29:187–91.
43. Wise M S, Arand D L, Auger R R, et al.Treatment of narcolepsy and other hypersomnias of central origin. Sleep, 2007; 30:1712–27.
44. Billiard M, Bassetti C, Dauvilliers Y, et al.EFNS guidelines on management of narcolepsy. Eur J Neurol, 2006; 13:1035–48.
45. Parkes J D, Dahlitz M. Amphetamine prescription. Sleep, 1993; 16:201–03.
46. Mitler MM, Aldrich MS, Koob G F, et al.Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep, 1994; 17:352–71.
47. Ryan D H, Bray G A, Helmcke F, et al.Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res, 1999; 7:313–22.
48. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep, 2006; 29:939–46.
49. Husain A M, Ristanovic R K, Bogan R K. Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med, 2009; 10:661–63.
50. Feldman N T. Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing. Sleep Breath, 2010; 14:77–79.
51. Lammers G J, Bassetti C, Billiard M, et al.Sodium oxybate is an effective and safe treatment for narcolepsy. Sleep Med, 2010; 11:105–06.
52. Parkes D. Introduction to the mechanism of action of different treatments of narcolepsy. Sleep, 1994; 17:S93–96.
53. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol, 1997; 52:27–78.
54. Nishino S, Arrigoni J, Shelton J, et al.Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep, 1993; 16:706–12.
55. Niederhofer H. Atomoxetine also effective in patients suffering from narcolepsy? Sleep, 2005; 28:1189.
56. U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med, 2004; 5:119–23.
57. U.S. Xyrem Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep, 2003; 26:31–35.
58. Thorpy MJ, Snyder M, Aloe F S, et al.Short-term triazolam use improves nocturnal sleep of narcoleptics. Sleep, 1992; 15:212–16.
59. Lin J S, Dauvilliers Y, Arnulf I, et al.An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin–/–mice and patients. Neurobiol Dis, 2008; 30:74–83.
60. Dauvilliers Y. Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol, 2006; 60:153.
61. Fronczek R, Verschuuren J, Lammers G J. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol, 2007; 254:1607–08.
62. Arias-Carrion O, Murillo-Rodriguez E. Cell transplantation: a future therapy for narcolepsy? CNS Neurol Disord Drug Targets, 2009; 8:309–14.